Sugi Predict

Sugi Predict / Compounds / SCHEMBL8908294

SCHEMBL8908294

SCHEMBL8908294

Cc1nc2cc(C(C(=O)C(C)(C)C)N(C)C)ccc2s1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 6/20 0.49
▸ NPC1 O15118 5/20 0.49
▸ SMN1; SMN2 Q16637 4/20 0.49
▸ TRPV1 Q8NER1 1/20 0.46
▸ HSD17B10 Q99714 2/20 0.43
▸ ALDH1A1 P00352 3/20 0.41
▸ POLB P06746 2/20 0.41
▸ CASP3 P42574 1/20 0.41
▸ SENP7 Q9BQF6 1/20 0.41
▸ MAPT P10636 3/20 0.40
▸ LDHA P00338 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.38
▸ TP53 P04637 2/20 0.38
▸ PKM P14618 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ HDAC4 P56524 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ KMT2A Q03164 1/20 0.36
▸ DYRK1A Q13627 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13179179 0.89 NPC1 (0.46) RAB9ANPC1SMN1; SMN2TRPV1HSD17B10
SCHEMBL753866 0.85 RAB9A (0.56) RAB9ANPC1SMN1; SMN2TRPV1HSD17B10
SCHEMBL8922089 0.85 RAB9A (0.52) RAB9ANPC1SMN1; SMN2TRPV1HSD17B10
SCHEMBL13747654 0.84 RAB9A (0.51) RAB9ANPC1SMN1; SMN2TRPV1HSD17B10
SCHEMBL888874 0.83 RAB9A (0.50) RAB9ANPC1SMN1; SMN2TRPV1HSD17B10
SCHEMBL8927076 0.82 NPC1 (0.49) RAB9ANPC1SMN1; SMN2TRPV1HSD17B10
SCHEMBL19333995 0.78 SMN1; SMN2 (0.45) RAB9ANPC1SMN1; SMN2TRPV1HSD17B10
SCHEMBL18731289 0.75 SMN1; SMN2 (0.47) RAB9ANPC1SMN1; SMN2HSD17B10ALDH1A1
SCHEMBL1991667 0.73 SMN1; SMN2 (0.47) RAB9ANPC1SMN1; SMN2TRPV1HSD17B10
SCHEMBL2631638 0.71 NPC1 (0.59) RAB9ANPC1SMN1; SMN2TRPV1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10752611-B2 Benzimidazole derivatives ENANTA PHARMACEUTICALS, INC. (US) 2020-08-25 — — US disclosed
US-9127021-B2 Hepatitis C virus inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2015-09-08 — — US disclosed
US-8673954-B2 Benzimidazole derivatives ENANTA PHARMACEUTICALS, INC. (US) 2014-03-18 — — US disclosed
US-8637561-B2 Linked diimidazole derivatives ENANTA PHARMACEUTICALS, INC. (US) 2014-01-28 — — US disclosed
US-8637561-B2 Linked diimidazole derivatives ENANTA PHARMACEUTICALS, INC. (US) 2014-01-28 — — US disclosed
US-20130295049-A1 LINKED DIBENZIMIDAZOLE ANTIVIRALS ENANTA PHARMACEUTICALS, INC (US) 2013-11-07 — — US disclosed
US-8188132-B2 Linked dibenzimidazole derivatives ENANTA PHARMACEUTICALS, INC. (US) 2012-05-29 — — US disclosed
US-20120076756-A1 NOVEL BENZIMIDAZOLE DERIVATIVES ENANTA PHARMACEUTICALS, INC. 2012-03-29 — — US disclosed
US-20120076756-A1 NOVEL BENZIMIDAZOLE DERIVATIVES ENANTA PHARMACEUTICALS, INC. 2012-03-29 — — US disclosed
US-20110300104-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2011-12-08 — — US disclosed
US-20110250172-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2011-10-13 — — US disclosed
US-20110250172-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2011-10-13 — — US disclosed
US-20110142798-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2011-06-16 — — US disclosed
US-20110142798-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2011-06-16 — — US disclosed
US-20100226883-A1 LINKED DIIMIDAZOLE DERIVATIVES ENANTA PHARMACEUTICALS, INC. 2010-09-09 — — US disclosed
US-20100221214-A1 LINKED DIBENZIMIDAZOLE DERIVATIVES ENANTA PHARMACEUTICALS, INC. 2010-09-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110300104-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, SLC10A1, EIF2AK2 RAB9A 3036/4885NPC1 36/4885SMN1; SMN2 4162/4885
US-20110250172-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, SLC10A1, EIF2AK2 RAB9A 3036/4885NPC1 36/4885SMN1; SMN2 4162/4885
US-20120076756-A1 NOVEL BENZIMIDAZOLE DERIVATIVES EIF2AK2, ZC3HAV1, HAVCR2 RAB9A 3679/4885NPC1 159/4885SMN1; SMN2 3741/4885
US-20110142798-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, SLC10A1, EIF2AK2 RAB9A 3036/4885NPC1 36/4885SMN1; SMN2 4162/4885
US-20100226883-A1 LINKED DIIMIDAZOLE DERIVATIVES EIF2AK2, ZC3HAV1, HAVCR2 RAB9A 3384/4885NPC1 106/4885SMN1; SMN2 3298/4885
US-20100221214-A1 LINKED DIBENZIMIDAZOLE DERIVATIVES EIF2AK2, NSUN2, ZC3HAV1 RAB9A 3788/4885NPC1 273/4885SMN1; SMN2 3515/4885
US-20130295049-A1 LINKED DIBENZIMIDAZOLE ANTIVIRALS EIF2AK2, ZC3HAV1, NSUN2 RAB9A 3937/4885NPC1 448/4885SMN1; SMN2 3504/4885
US-10752611-B2 Benzimidazole derivatives EIF2AK2, ZC3HAV1, ZC3HAV1L RAB9A 3990/4885NPC1 162/4885SMN1; SMN2 3511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.